REFERENCES
2. Desselas E, Thuret I, Kaguelidou F, et al. Mortality in children with sickle cell disease in mainland France from 2000 to 2015. Haematologica. 2020;105:e440-443.
3. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115:3447-52.
4. Oteng-Ntim E, Meeks D, Seed PT, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood. 2015;125:3316-25.
5. Boafor TK, Olayemi E, Galadanci N, et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG. 2016;123:691-8.
6. Rahimy MC, Gangbo A, Adjou R, Deguenon C, Goussanou S, Alihonou E. Effect of active prenatal management on pregnancy outcome in sickle cell disease in an African setting. Blood. 2000;96:1685-9.
7. Kuo K, Caughey AB. Contemporary outcomes of sickle cell disease in pregnancy. Am J Obstet Gynecol. 2016;215:505.e1-5.
8. Said Al Harthi S, Arulappan J, Al Yazeedi B, Al Zaabi AHS. Adverse pregnancy, fetal and neonatal outcomes in women with sickle cell disease in a Middle Eastern country. Womens Health. 2024;20:17455057231220188.
9. Malinowski AK, Shehata N, D'Souza R, et al. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood. 2015;126:2424-35; quiz 2437.
10. Ha TK, Boulet SL, Cotsonis G, Geary F, Jamieson DJ, Lindsay M. Association of sickle cell disease with severe maternal morbidity. Obstet Gynecol. 2023;141:163-9.
11. Chang JN, Magann EF, Novotny SA, et al. Maternal/perinatal outcome in women with sickle cell disease: a comparison of two time periods. South Med J. 2018;111:742-5.
12. Lesage N, Deneux Tharaux C, Saucedo M, et al. Maternal mortality among women with sickle-cell disease in France, 1996-2009. Eur J Obstet Gynecol Reprod Biol. 2015;194:183-8.
13. Adesina OO, Brunson A, Fisch SC, et al. Pregnancy outcomes in women with sickle cell disease in California. Am J Hematol. 2023;98:440-8.
14. Early ML, Eke AC, Gemmill A, Lanzkron S, Pecker LH. Severe maternal morbidity and mortality in sickle cell disease in the national inpatient sample, 2012-2018. JAMA Netw Open. 2023;6:e2254552.
15. Sharma D, Kozanoğlu I, Ataga KI, et al. Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel. Blood Adv. 2024;8:1018-29.
16. Ngô C, Kayem G, Habibi A, et al. Pregnancy in sickle cell disease: maternal and fetal outcomes in a population receiving prophylactic partial exchange transfusions. Eur J Obstet Gynecol Reprod Biol. 2010;152:138-42.
17. Sobczyk O, Gottardi E, Lefebvre M, et al. Evaluation of a prophylactic transfusion program on obstetric outcomes in pregnant women with sickle cell disease: a single centre retrospective cohort study. Eur J Obstet Gynecol Reprod Biol. 2023;290:103-8.
18. Aghamolaei T, Pormehr-Yabandeh A, Hosseini Z, Roozbeh N, Arian M, Ghanbarnezhad A. Pregnancy in the sickle cell disease and fetomaternal outcomes in different sickle cell genotypes: a systematic review and meta-analysis. Ethiop J Health Sci. 2022;32:849-64.
19. Early M L, Strodel R J, Lake I V, et al. Acceptable, hopeful, and useful: development and mixed-method evaluation of an educational tool about reproductive options for people with sickle cell disease or trait. J Assist Reprod Genet. 2022;39:183-93.
21. Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. Eur Respir Rev. 2016;25:431-7.
22. Pecker LH, Kuo KHM. Go the distance: reproductive health care for people with sickle cell disease. Hematol Oncol Clin North Am. 2022;36:1255-70.
23. Pecker LH, Hussain S, Christianson MS, Lanzkron S. Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the multicenter study of hydroxycarbamide. Br J Haematol. 2020;191:880-7.
24. Garba SR, Makwe CC, Osunkalu VO, et al. Ovarian reserve in Nigerian women with sickle cell anaemia: a cross- sectional study. J Ovarian Res. 2021;14:174.
25. Malan V, Bussières L, Winer N, et al. SAFE 21 Study Group. Effect of cell-free dna screening vs direct invasive diagnosis on miscarriage rates in women with pregnancies at high risk of trisomy 21: a randomized clinical trial. JAMA. 2018;320:557-65.
26. van Campen J, Silcock L, Yau S, et al. A novel non-invasive prenatal sickle cell disease test for all at-risk pregnancies. Br J Haematol. 2020;190:119-24.
27. Smith-Whitley K. Complications in pregnant women with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2019;2019:359-66.
29. Lee MT, Piomelli S, Granger S, et al. STOP Study Investigators. Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results. Blood. 2006;108:847-52.
30. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325:1476-81.
31. Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood. 2016;127:820-8.
32. Savale L, Habibi A, Lionnet F, et al. Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. Eur Respir J. 2019;54:1900585.
33. Lim JI, Niec M, Sun J, Cao D. Longitudinal assessment of retinal thinning in adults with and without sickle cell retinopathy using spectral-domain optical coherence tomography. JAMA Ophthalmol. 2021;139:330-7.
34. Menaa F, Khan BA, Uzair B, Menaa A. Sickle cell retinopathy: improving care with a multidisciplinary approach. J Multidiscip Healthc. 2017;10:335-46.
35. Fountas A, Van Uum S, Karavitaki N. Opioid-induced endocrinopathies. Lancet Diabetes Endocrinol. 2020;8:68-80.
36. Tan EK, Tan EL. Alterations in physiology and anatomy during pregnancy. Best Pract Res Clin Obstet Gynaecol. 2013;27:791-802.
37. Inparaj S, Buckingham M, Oakley L, Seed PT, Lucas S, Oteng-Ntim E. Pulmonary complications for women with sickle cell disease in pregnancy: systematic review and meta-analysis. Thorax. 2020;75:568-75.
38. Oteng-Ntim E, Ayensah B, Knight M, Howard J. Pregnancy outcome in patients with sickle cell disease in the UK-a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. Br J Haematol. 2015;169:129-37.
39. Osunkwo I, James J, El-Rassi F, et al. Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: a comparative analysis of high- and low- to middle-income countries for the international sickle cell world assessment survey. Am J Hematol. 2022;97:1055-64.
40. Darlington F, Acha BM, Roshan T, et al. Opioid-related disorders among pregnant women with sickle cell disease and adverse pregnancy outcomes. Pain Med. 2020;21:3087-93.
41. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143:697-706.
42. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194:1311-5.
43. Seaman CD, Yabes J, Li J, Moore CG, Ragni MV. Venous thromboembolism in pregnant women with sickle cell disease: a retrospective database analysis. Thromb Res. 2014;134:1249-52.
44. Agarwal S, Stanek JR, Vesely SK, et al. Pregnancy-related thromboembolism in women with sickle cell disease: an analysis of national medicaid data. Am J Hematol. 2023;98:1677-84.
45. Srisuwananukorn A, Raslan R, Zhang X, et al. Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. Blood Adv. 2020;4:1978-86.
46. Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica. 2014;99:392-8.
47. Grouzi E, Pouliakis A, Aktypi Α, et al. Pregnancy and thrombosis risk for women without a history of thrombotic events: a retrospective study of the real risks. Thromb J. 2022;20:60.
48. Oteng-Ntim E, Pavord S, Howard R, et al. British Society for Haematology Guideline. Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline. Br J Haematol. 2021;194:980-95.
49. Serjeant GR, Loy LL, Crowther M, Hambleton IR, Thame M. Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol. 2004;103:1278-85.
50. Kroner BL, Hankins JS, Pugh N, et al. Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. Am J Hematol. 2022;97:603-12.
51. Oakley LL, Mitchell S, von Rege I, et al. Perinatal outcomes in women with sickle cell disease: a matched cohort study from London, UK. Br J Haematol. 2022;196:1069-75.
52. Lopinto J, Gendreau S, Berti E, Bartolucci P, Habibi A, Mekontso Dessap A. Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis. Haematologica. 2022;107:1914-21.
53. Walter O, Cougoul P, Maquet J, et al. Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease. Blood. 2022;139:3771-77.
54. Wang F, Mandelbrot L, Affo L, et al. Drepagest Study Group. Impact of prenatal corticosteroid therapy on sickle cell disease in pregnant women. Int J Gynaecol Obstet. 2023;163:243-55.
55. Adam-Raileanu A, Miron I, Lupu A, et al. Fetal growth restriction and its metabolism-related long-term outcomes-underlying mechanisms and clinical implications. Nutrients. 2025;17:555.
56. Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ. 1991;303:671-5.
57. Crispi F, Miranda J, Gratacós E. Long-term cardiovascular consequences of fetal growth restriction: biology, clinical implications, and opportunities for prevention of adult disease. Am J Obstet Gynecol. 2018;218:S869-79.
58. MCGRE - Filière santé maladies rares. Available from: https://filiere-mcgre.fr. [Last accessed on 19 June 2025].
59. Ezenwosu OU, Olawepo JO, Lacroix-Willliamson LJ, et al. Health education to promote knowledge about sickle cell disease and newborn screening in pregnant women: a community-based pilot study using the healthy beginning initiative. BMC Pregnancy Childbirth. 2024;24:321.
61. Hong K, Hwang H, Han H, et al. Perspectives on antenatal education associated with pregnancy outcomes: systematic review and meta-analysis. Women Birth. 2021;34:219-30.
62. Gool JD, Hirche H, Lax H, De Schaepdrijver L. Folic acid and primary prevention of neural tube defects: a review. Reprod Toxicol. 2018;80:73-84.
63. Schnog JB, van der Dijs FP, Fokkema MR, Muskiet FD, Muskiet FA. Folate status assessment and folic acid supplements in sickle cell disease. J Pediatr Hematol Oncol. 2001;23:548.
64. Habibi A, Arlet JB, Stankovic K, et al. French guidelines for the management of adult sickle cell disease: 2015 update. Rev Med Interne. 2015;36:5S3-84.
65. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613-22.[DOI:10.1056/NEJMoa1704559].
67. Nolan VG, Nottage KA, Cole EW, Hankins JS, Gurney JG. Prevalence of vitamin D deficiency in sickle cell disease: a systematic review. PLoS One. 2015;10:e0119908.
68. Montalembert M, Voskaridou E, Oevermann L, et al; All ESCORT HU Investigators. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. Am J Hematol. 2021;96:1223-31.
69. Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D. Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. Eur J Haematol. 1996;56:326-8.
70. Little JA, McGowan VR, Kato GJ, et al. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006;91:1076-83.
71. FDA. Available from: https://www.fda.gov/drugs. [Last accessed on 19 June 2025].
72. Piccioni MG, Capone C, Vena F, et al. Use of deferoxamine (DFO) in transfusion-dependent β-thalassemia during pregnancy: a retrospective study. Taiwan J Obstet Gynecol. 2020;59:120-2.
73. Singer ST, Vichinsky EP. Deferoxamine treatment during pregnancy: Is it harmful? Am J Hematol. 1999;60:24-6.
74. Diamantidis MD, Neokleous N, Agapidou A, et al. Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic? Int J Hematol. 2016;103:537-44.
75. Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA. 2014;311:1760-9.
76. Abu-Raya B. Extending timing of immunization against pertussis during pregnancy and protection of premature infants from whooping cough disease. Clin Infect Dis. 2021;73:e2509-11.
77. Ciapponi A, Bardach A, Mazzoni A, et al. Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: a rapid review. Vaccine. 2021;39:5891-908.
78. Joseph L, De Luna G, Bernit E, et al. A study of 28 pregnant women with sickle cell disease and COVID-19: elevated maternal and fetal morbidity rates. Haematologica. 2024;109:1562-5.
79. Ribeil JA, Labopin M, Stanislas A, et al. Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: a retrospective survey by the international sickle cell disease observatory. Am J Hematol. 2018;93:794-802.
80. Yılmaz Baran Ş, Kozanoğlu İ, Korur A, et al. Role of prophylactic and therapeutic red blood cell exchange in pregnancy with sickle cell disease: maternal and perinatal outcomes. J Clin Apher. 2021;36:283-90.
81. Colpo A, Marson P, Pavanello F, et al. Therapeutic apheresis during pregnancy: a single center experience. Transfus Apher Sci. 2019;58:652-8.
82. Malinowski AK, Kuo KHM, Tomlinson GA, Palcu P, Ward R, Shehata N. Distinct maternal and fetal pregnancy outcomes in women with sickle cell disease can be predicted using routine clinical and laboratory data. Br J Haematol. 2021;194:1063-73.
83. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4:327-55.
84. Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. a randomized cooperative study. N Engl J Med. 1988;319:1447-52.
85. Habibi A, Benachi A, Lecarpentier E. Managing pregnancy in patients with sickle cell disease from a transfusion perspective. Hematology Am Soc Hematol Educ Program. 2023;2023:640-5.
86. Joseph L, Driessen M. A comprehensive view of pregnancy in patients with sickle cell disease in high-income countries: the need for robust data and further decline in morbidity and mortality. Lancet Haematol. 2024;11:e75-84.
87. Alan S, Sharma D, Pecker LH. Prophylactic red cell transfusions for sickle cell disease pregnancy: increased use of therapy could transform outcomes. Curr Opin Hematol. 2024;31:285-93.
88. Shankar D, Stanek CJ, Bangudi S, et al. Contraception, pregnancy, and STI counseling and care among transitioning young adults with sickle cell disease. Blood Adv. 2023;7:6668-71.
89. Ware RE, Marahatta A, Ware JL, McElhinney K, Dong M, Vinks AA. Hydroxyurea exposure in lactation: a pharmacokinetics study (HELPS). J Pediatr. 2020;222:236-9.
90. Narbey D, Habibi A, Chadebech P, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol. 2017;92:1340-8.
